<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075891</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.113322</org_study_id>
    <nct_id>NCT03075891</nct_id>
  </id_info>
  <brief_title>Oracea Soolantra Association in Patients With Severe Rosacea</brief_title>
  <acronym>ANSWER</acronym>
  <official_title>Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream
      associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1%
      topical cream associated with Placebo in the treatment of severe Rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Percent change from Baseline in Inflammatory Lesion count)</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent change from Baseline in Inflammatory Lesion count</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Ivermectin 1% cream + Doxycycline 40 mg MR capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin 1% cream + Oral placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 1% cream</intervention_name>
    <description>Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks</description>
    <arm_group_label>Ivermectin 1% cream + Doxycycline 40 mg MR capsules</arm_group_label>
    <arm_group_label>Ivermectin 1% cream + Oral placebo capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 40 mg MR (30 mg Immediate Release &amp; 10 mg Delayed Release beads) capsules</intervention_name>
    <description>1 Capsule once-daily for 12 weeks</description>
    <arm_group_label>Ivermectin 1% cream + Doxycycline 40 mg MR capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral placebo capsules</intervention_name>
    <description>1 Capsule once-daily for 12 weeks</description>
    <arm_group_label>Ivermectin 1% cream + Oral placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject age â‰¥ 18 years or older;

          -  Subject with a minimum of 20 but not more than 70 inflammatory lesions (papules and
             pustules) of rosacea on the face at Baseline visit;

          -  Subject with severe rosacea with papulopustular lesions (according to the
             Investigator's Global Assessment, IGA score rated 4);

          -  Female subjects of childbearing potential with a negative urine pregnancy test (UPT);

          -  Female subjects of childbearing potential must practice a highly effective method of
             contraception during the study;

        Exclusion Criteria:

          -  Subjects with particular forms of rosacea or other concomitant facial dermatoses that
             may be confounded with rosacea;

          -  Subjects with more than 2 nodules of rosacea on the face;

          -  Subjects with any uncontrolled chronic or serious disease or medical condition that
             may either interfere with the interpretation of the clinical trial results, or with
             optimal participation in the study or would present a significant risk to the
             subject;

          -  Subjects with known or suspected allergies or sensitivities to any component of the
             investigational and non-investigational products, including the active ingredients
             doxycycline and ivermectin;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabien Audibert</last_name>
    <phone>+ 33 4 92 38 30 34</phone>
    <email>fabien.audibert@galderma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajeev Chavda, MD</last_name>
    <phone>+ 33 4 92 95 29 28</phone>
    <email>rajeev.chavda@galderma.com</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
